Literature DB >> 21766413

Targeted siRNA delivery to diseased microvascular endothelial cells: cellular and molecular concepts.

Piotr S Kowalski1, Niek G J Leus, Gerrit L Scherphof, Marcel H J Ruiters, Jan A A M Kamps, Grietje Molema.   

Abstract

Increased insight in the role of endothelial cells in the pathophysiology of cancer, inflammatory and cardiovascular diseases, has drawn great interest in pharmacological interventions aiming at the endothelium in diseased sites. Their location in the body makes them suitable targets for therapeutic approaches based on targeted drug delivery. Functional heterogeneity of the microvascular bed in normal organ homeostasis has been appreciated for a long time, and more recent studies have revealed heterogeneity in endothelial reactivity to inflammatory stimuli as well. Upon stimulation, each organ displays a vascular bed specific pattern of cell adhesion molecules providing challenging opportunities to deliver drugs or small RNAs to organ specific (micro)vascular endothelial subsets. In this review we introduce general concepts of endothelial heterogeneity in relation to disease state and its consequences for targeted therapeutic interventions. Furthermore, we will describe novel approaches to interfere with endothelial cell engagement in disease with a main focus on siRNA therapeutics and currently used nonviral lipid and polymer-based siRNA delivery systems. The last part of this review addresses some technical issues that are essential in proving the concept of target mRNA knock down in a vascular bed specific manner, and the further development of effective endothelial cell specific drug delivery devices.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21766413     DOI: 10.1002/iub.487

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  12 in total

Review 1.  Targeting therapeutics to endothelium: are we there yet?

Authors:  Raisa Yu Kiseleva; Patrick M Glassman; Colin F Greineder; Elizabeth D Hood; Vladimir V Shuvaev; Vladimir R Muzykantov
Journal:  Drug Deliv Transl Res       Date:  2018-08       Impact factor: 4.617

2.  Ionizable Amino-Polyesters Synthesized via Ring Opening Polymerization of Tertiary Amino-Alcohols for Tissue Selective mRNA Delivery.

Authors:  Piotr S Kowalski; Umberto Capasso Palmiero; Yuxuan Huang; Arnab Rudra; Robert Langer; Daniel G Anderson
Journal:  Adv Mater       Date:  2018-07-05       Impact factor: 30.849

Review 3.  Current siRNA targets in atherosclerosis and aortic aneurysm.

Authors:  Leena Pradhan-Nabzdyk; Chenyu Huang; Frank W LoGerfo; Christoph S Nabzdyk
Journal:  Discov Med       Date:  2014-05       Impact factor: 2.970

Review 4.  Fighting against kidney diseases with small interfering RNA: opportunities and challenges.

Authors:  Cheng Yang; Chao Zhang; Zitong Zhao; Tongyu Zhu; Bin Yang
Journal:  J Transl Med       Date:  2015-02-01       Impact factor: 5.531

Review 5.  Small-nucleic-acid-based therapeutic strategy targeting the transcription factors regulating the vascular inflammation, remodeling and fibrosis in atherosclerosis.

Authors:  Sung Won Youn; Kwan-Kyu Park
Journal:  Int J Mol Sci       Date:  2015-05-22       Impact factor: 5.923

Review 6.  Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm.

Authors:  Melissa Howard; Blaine J Zern; Aaron C Anselmo; Vladimir V Shuvaev; Samir Mitragotri; Vladimir Muzykantov
Journal:  ACS Nano       Date:  2014-05-07       Impact factor: 15.881

7.  SiRNA Crosslinked Nanoparticles for the Treatment of Inflammation-induced Liver Injury.

Authors:  Yaqin Tang; Ziying Zeng; Xiao He; Tingting Wang; Xinghai Ning; Xuli Feng
Journal:  Adv Sci (Weinh)       Date:  2016-09-02       Impact factor: 16.806

Review 8.  Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes.

Authors:  Marloes L de Groote; Pernette J Verschure; Marianne G Rots
Journal:  Nucleic Acids Res       Date:  2012-09-21       Impact factor: 16.971

9.  Vascular immunotargeting to endothelial determinant ICAM-1 enables optimal partnering of recombinant scFv-thrombomodulin fusion with endogenous cofactor.

Authors:  Colin F Greineder; Ann-Marie Chacko; Sergei Zaytsev; Blaine J Zern; Ronald Carnemolla; Elizabeth D Hood; Jingyan Han; Bi-Sen Ding; Charles T Esmon; Vladimir R Muzykantov
Journal:  PLoS One       Date:  2013-11-14       Impact factor: 3.240

10.  Endothelium-targeted delivery of dexamethasone by anti-VCAM-1 SAINT-O-Somes in mouse endotoxemia.

Authors:  Ranran Li; Piotr S Kowalski; Henriëtte W M Morselt; Ilona Schepel; Rianne M Jongman; Adnan Aslan; Marcel H J Ruiters; Jan G Zijlstra; Grietje Molema; Matijs van Meurs; Jan A A M Kamps
Journal:  PLoS One       Date:  2018-05-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.